News

The draft guideline "STABILITY TESTING OF DRUG SUBSTANCES AND DRUG PRODUCTS" of the ICH was published in April 2025 and is now available for public comment.

More

In November 2024, the US FDA inspected a French sterile manufacturer of prescription and OTC medicines. The inspectors found significant GMP violations. Deficiencies were cited in the handling of complaints, the microbiological control of aseptic processes and the cleaning and maintenance of production equipment.

More

The U.S. Food and Drug Administration (FDA) has issued a Warning Letter to a Chinese OTC manufacturer, highlighting CGMP deficiencies in raw material testing, process controls, stability testing, and quality oversight.

More

In a recent Warning Letter, the FDA outlines severe GMP deficiencies in the manufacture of OTC hand sanitizers and antibacterial soaps, including missing identity testing, lack of stability data, and absent process validation. Critical raw materials such as glycerin and ethanol were accepted without proper testing – despite their known risk of contamination with diethylene glycol (DEG), ethylene glycol (EG), or methanol, substances that have caused fatal poisoning incidents worldwide.

More

The FDA recently issued Warning Letters to several pharmaceutical companies for violating CGMP regulations and expectations on Quality Oversight.

More

The European GMP Auditor Association has published a revised and further improved version of its GMP Auditors Reference Handbook. It is available on the website of the association.

More

In the US, inspections can happen announced; companies cannot choose when these inspections happen. Now, supported by an Executive Order, foreign firms will now be treated the same.

More

Back in October/November 2024, the FDA carried out an inspection at a US manufacturer of OTC products and uncovered a number of GMP deficiencies, including in process validation, which has now led to a warning letter. Continue reading.

More

The Investigations Operations Manual (IOM) is the primary operational reference for FDA investigators. Although primarily used internally by FDA staff, it is available publicly. The Manual has now been revised.

More

The US FDA inspected an Indian API manufacturer from 4 to 12 September 2024 and found serious GMP violations. The deficiencies relate in particular to inadequate cleaning procedures and the associated risk of contamination, inadequate handling of quality deficiencies and violations of data integrity.

More
x